Table of Contents Author Guidelines
Journal of Pharmaceutics
Volume 2018, Article ID 7916368, 7 pages
https://doi.org/10.1155/2018/7916368
Research Article

In Vitro and In Vivo Quality Evaluation of Glibenclamide Tablets Marketed in Addis Ababa, Ethiopia

1Department of Pharmacy, College of Health Sciences, Wollo University, P.O. Box. 1145, Dessie, Ethiopia
2Department of Pharmaceutical Chemistry and Pharmacognosy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box. 1176, Addis Ababa, Ethiopia

Correspondence should be addressed to Ayenew Ashenef; te.ude.uaa@fenehsa.weneya

Received 14 May 2018; Accepted 26 June 2018; Published 18 July 2018

Academic Editor: Srinivas Mutalik

Copyright © 2018 Haile Kassahun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Al-Tahami, “A comparative quality study of selected locally manufactured and imported medicines in Yemeni market,” Yemeni Journal for Medical Sciences, vol. 4, pp. 6–6, 2010. View at Google Scholar
  2. R. B. Taylor, O. Shakoor, R. H. Behrens et al., “Pharmacopoeial quality of drugs supplied by Nigerian pharmacies,” The Lancet, vol. 357, no. 9272, pp. 1933–1936, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Raheela, S. Gauhar, and S. B. S. Naqvi, “Pharmaceutical evaluation of different brands of levofloxacin tablets (250 mg) available in local market of Karachi (Pakistan),” International Journal of Current Pharmaceutical Research, vol. 3, no. 1, pp. 15–22, 2011. View at Google Scholar
  4. N. C. Ngwuluka, K. Lawal, P. O. Olorunfemi, and N. A. Ochekpe, “Post-market in vitro bioequivalence study of six brands of ciprofloxacin tablets/caplets in Jos, Nigeria,” Scientific Research and Essays, vol. 4, no. 4, pp. 298–305, 2009. View at Google Scholar · View at Scopus
  5. US Food and Drug Administration, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, US Food and Drug Administration, Guidance for Industry, Rockville, Md, USA, 2004, https://www.fda.gov/downloads/drugs/guidance’s/ucm070124pdf.
  6. M. A. Hassali, J. Thambyappa, F. Saleem, N. ul Haq, and H. Aljadhey, “Generic substitution in Malaysia: Recommendations from a systematic review,” Journal of Applied Pharmaceutical Science, vol. 2, no. 8, pp. 159–164, 2012. View at Google Scholar · View at Scopus
  7. R. Chereson, Basic Pharmacokinetics: Bioavailability, Bioequivalence and Drug Selection, 1996, http://www.scribd.com/doc/496701/basic-pharmacokineticsbioavaiabiltyy#scribd.
  8. M. Idries Amjad, E. Mohammed, E. Mahmoud, and E. Kamal, “Interchangeability and Comparative Effectiveness between Micronized and Non-micronized Products of Glibenclamide Tablets,” Sudan Journal of Medical Sciences, vol. 7, no. 3, pp. 153–159, 2012. View at Google Scholar
  9. A. Javaid, R. Hasan, A. Zaib, and S. Mansoor, “A comparative study of the effects of hypoglycemic agents on serum electrolytes in the diabetic patients.,” Pakistan Journal of Pharmaceutical Sciences, vol. 20, no. 1, pp. 67–71, 2007. View at Google Scholar · View at Scopus
  10. D. El-Sabawi, S. Alja, and I. I. Hamdan, “Pharmaceutical evaluation of glibenclamide products available in the Jordanian market,” African Journal of Pharmacy and Pharmacology, vol. 7, no. 22, pp. 1464–1470, 2013. View at Publisher · View at Google Scholar
  11. A. Elhamili, J. Bergquist, M. El-Attug et al., “Pharmaceutical evaluation of Type II oral antidiabetic agent,” International Journal of Pharma Research & Review, vol. 3, no. 6, pp. 1–9, 2014. View at Google Scholar
  12. E. Osonwa Uduma, A. Agboke Ayodeji, C. Amadi Rosemary, O. Ogbonna, and C. Opurum Christian, “Bioequivalence studies on some selected brands of ciprofloxacin hydrochloride tablets in the Nigerian market with ciproflox® as innovator brand,” Journal of Applied Pharmaceutical Science, vol. 1, no. 6, pp. 80–84, 2011. View at Google Scholar · View at Scopus
  13. A. M. Olusola, A. I. Adekoya, and O. J. Olanrewaju, “Comparative evaluation of physicochemical properties of some commercially available brands of metformin Hcl tablets in Lagos, Nigeria,” Journal of Applied Pharmaceutical Science, vol. 2, no. 2, pp. 41–44, 2012. View at Google Scholar · View at Scopus
  14. The United State Pharmacopoeia (USP), National Formulary, M. D. Asian, Ed., USP 24/NF 19, United State Pharmacopoeial Convention, Rockville, Md, USA, 2000.
  15. United States Pharmacopoeia (USP), National Formulary, vol. 1 of USP 30/NF 25, United States Pharmacopoeial Convention Inc., Rockville, Md, USA, 2007.
  16. British Pharmacopoeia (BP), The Her Majesty’s Stationary Office, vol. III, London, UK, 2009.
  17. A. Saidu, A. Mann, and S. Balogun, “The hypoglycemic effect of aqueous extract of the anacardium occidentale linn leaves grown in Nigeria on normoglycemic Albino Rats,” Journal of Emerging Trends in Engineering and Applied Sciences, vol. 3, no. 2, pp. 302–308, 2012. View at Google Scholar
  18. S. O. Momoh, M. M. Yusuf, C. O. C. Adamu et al., “Evaluation of the phytochemical composition and hypoglycaemic activity of methanolic leaves extract of costus afer in albino rats,” British Journal of Pharmaceutical Research, vol. 1, no. 1, pp. 1–18, 2011. View at Publisher · View at Google Scholar
  19. L. Nahar, F. Ripa, A. H. Zulfiker, and M. Rokonuzzaman, “Comparative study of antidiabetic effect of Abroma augusta and Syzygium cumini on alloxan induced diabetic rat,” Agriculture and Biology Journal of North America (ABJNA), vol. 1, no. 6, pp. 1268–1272, 2010. View at Publisher · View at Google Scholar
  20. M. Z. Zaruwa, J. Manosroi, T. Akihisa, W. Manosroi, and A. Manosroi, “Anti-diabetic activity of Anogeissus acuminata a medicinal plant selected from the Thai medicinal plant recipe database MANOSROI II,” Wudpecker Journal of Medicinal Plants, vol. 1, pp. 11–18, 2012. View at Google Scholar
  21. T. S. Oishi, Md. A. Haque, I. Dewan et al., “Comparative in Vitro Dissolution Study of Some Ciprofloxacin Generic Tablets under Biowaiver Conditions by Rp-Hplc,” International Journal of Pharmaceutical Sciences and Research, vol. 2, no. 12, pp. 3129–3135, 2011. View at Google Scholar
  22. M. A. Odeniyi, O. A. Adegoke, R. B. Adereti, O. A. Odeku, and O. A. Itiola, “Comparative analysis of eight brands of sulfadoxine-pyrimethamine tablets,” Tropical Journal of Pharmaceutical Research, vol. 2, no. 1, 2003. View at Publisher · View at Google Scholar
  23. C. O. Ogah and F. F. Kadejo, “Analysis of brands of glibenclamide tablets in Lagos market,” Journal of Innovative Research in Engineering and Sciences, vol. 4, no. 2, pp. 466–471, 2013. View at Google Scholar
  24. K. A. Kishore and P. Amareshwar, “Quality evaluation and comparative study on tablet Formulations of different pharmaceutical companies,” Journal of Current Chemical & Pharmaceutical Sciences, vol. 2, no. 1, pp. 24–31, 2012. View at Google Scholar
  25. G. S. Hailu, G. B. Gutema, A. A. Asefaw et al., “Comparative assessment of the physicochemical and in-vitro bioavailability equivalence of co-trimoxazole tablets marketed in Tigray, Ethiopia,” International Journal of Pharmaceutical Sciences and Research, vol. 2, no. 12, pp. 3210–3218, 2011. View at Google Scholar
  26. J. Muaz, L. K. Gazali, G. U. Sadiq, and G. M. Tom, “Comparative in vitro evaluation of the pharmaceutical and chemical equivalence of multi-source generic ciprofloxacin hydrochloride tablets around Maiduguri metropolitan area,” Nigerian Journal of Pharmaceutical Sciences, vol. 8, no. 2, pp. 102–106, 2009. View at Google Scholar
  27. S. Dash, P. N. Murthy, L. Nath, and P. Chowdhury, “Kinetic modeling on drug release from controlled drug delivery systems,” Acta Poloniae Pharmaceutica. Drug Research, vol. 67, no. 3, pp. 217–223, 2010. View at Google Scholar · View at Scopus
  28. “US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Dissolution testing of immediate release solid oral dosage forms,” 2017, http://www.fda.gov/cder/Guidance/1713bp1.Pdf.
  29. S. Mutalik and N. Udupa, “Formulation development, in vitro and in vivo evaluation of membrane controlled transdermal systems of glibenclamide,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 8, no. 1, pp. 26–38, 2005. View at Google Scholar · View at Scopus